Large-Scale Production of AAV Vectors for Neurological Genetic Therapies
AAV VECTOR PRODUCTION FOR NEUROLOGICAL ATMPS: SCALABLE SUSPENSION PLATFORMS
Large-Scale Production of AAV Vectors for Neurological Genetic Therapies
CELL & GENE | RNA | BIOLOGICS
Proven Intelligence in Scalable Vector Manufacturing.
Executive Summary
Achieving sufficient yield and purity for adeno-associated virus (AAV) vectors targeting the central nervous system (CNS) presents a significant manufacturing challenge, often requiring high-dose formulations. Franklin Biolabs provides robust, scalable suspension-based AAV production platforms, from 2L to 500L+, designed to meet the demands of advanced therapy medicinal product (ATMP) programs targeting neurological indications. Our process development is informed by a deep understanding of international regulatory expectations (ICH guidelines), ensuring a clear path for Investigational Medicinal Product Dossier (IMPD) and IND submissions.
Frequently Asked Questions
Q: What are the primary CMC challenges when scaling AAV production for advanced therapeutics targeting the CNS?
The primary challenges involve achieving high vector yields with consistent purity and potency, especially given the large doses often required for CNS delivery. Managing the ratio of full to empty capsids and minimizing process-related impurities are key focus areas for building a robust CMC data package suitable for multi-jurisdictional IND and IMPD submissions.
Q: How does Franklin Biolabs ensure its AAV scalable suspension process meets global regulatory standards?
Our processes are developed with regulatory compliance as a foundational principle. We align with harmonized ICH guidelines and have extensive experience preparing data packages for both FDA and European authorities. This includes rigorous in-process controls, qualified analytical assays, and comprehensive characterization to support ATMP submissions in Switzerland and across the EU.
Q: What is the typical timeline for moving from a research-grade vector to an IND-enabling batch?
A well-defined process development and manufacturing strategy can significantly shorten timelines. Our teams operate on an 18-24 month timeline to advance candidates to IND. This accelerated path is possible due to our established platform processes and the deep institutional knowledge of our scientific leadership in navigating AAV manufacturing complexities.
Transitioning to High-Yield Suspension Platforms
The dose requirements for many AAV-based neurological therapies necessitate a move beyond traditional adherent cell culture systems. While adherent platforms using iCELLis® or scale-X™ fixed-bed bioreactors are suitable for certain applications, true large-scale production for prevalent CNS disorders depends on scalable suspension culture in single-use bioreactors. The historical development of methods like adenovirus-AAV hybrid systems underscores the long-standing need for production technologies that can meet clinical demand (PMID: 19618999).
Our approach focuses on optimizing upstream and downstream processes specifically for suspension systems. This includes:
Refining transfection parameters and media strategies for high-density cell cultures.
Developing and qualifying gene-of-interest-specific ddPCR and cell-based potency assays.
This focus on a robust, reproducible manufacturing process is a core component of de-risking clinical translation.
A Foundation of Preclinical and Regulatory Success
A scalable manufacturing process is only valuable if the resulting vector has a well-understood safety profile. Long-term safety is a particular point of scrutiny for therapies targeting non-dividing neuronal cells. Foundational large-scale preclinical evaluations have provided strong evidence that AAV vectors do not inherently predispose subjects to tumorigenesis, a finding that helps build confidence for long-term clinical applications (PMID: 16043099).
This historical safety data, combined with modern analytical characterization, forms the basis of a strong regulatory submission. The scientific leadership and core teams at Franklin Biolabs, which launched formally in 2024, carry forward a legacy of excellence, contributing to a 100% successful IND rate since 2019. This track record provides sponsors with confidence in our ability to navigate complex CMC requirements.
Our scientific leadership, formerly of the UPenn Vector Core, maintains a history of successful collaborations. A partnership initiated in 2023 produced an AAV vector that provided the foundation for a client’s gene therapy candidate, which is now advancing to preclinical studies. This collaboration transitioned seamlessly to Franklin Biolabs, ensuring uninterrupted program support for AAV-based gene therapy development.
For a deeper technical overview of capsid engineering and scalability considerations, our recent webinar provides additional context
. The insights from our scientific teams can help shape your vector design and manufacturing strategy from the earliest stages.
Franklin Biolabs offers a direct path from process development to large-scale, GxP-compliant AAV production. Our expertise in both the science and the regulatory landscape supports next-generation therapy programs targeting the most challenging neurological conditions.
Featured Video: Vector Ready: Where AAV projects begin and how they succeed – Franklin Biolabs
This webinar covers important factors for initiating AAV vector programs, focusing on capsid engineering, scalability, and preclinical safety profiling.
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.
